Claims
- 1. A compound of formula I:
- 2. The compound of claim 1 wherein R3 is hydrogen.
- 3. The compound of claim 1 wherein R1, R2 and R3 are each individually hydrogen, or (C1-C6)alkoxy; or R1 and R2 taken together are methylenedioxy and R3 is hydrogen or (C1-C6)alkoxy.
- 4. The compound of claim 1 wherein R7 or R8 is (C1-C6)alkoxy; or R7 and R8 taken together are methylenedioxy.
- 5. The compound of claim 1 wherein R7 and R8 taken together are methylenedioxy.
- 6. The compound of claim 1 wherein R2 is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro.
- 7. The compound of claim 1 wherein R8 is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro.
- 8. The compound of claim 1 wherein the bonds represented by—are both present.
- 9. The compound of claim 1 wherein wherein R1 is (C1-C6)alkoxy, nitro, hydroxy, or halo; or R1 and R2 taken together are methylenedioxy.
- 10. The compound of claim 1 wherein R2 is (C1-C6)alkoxy, nitro, hydroxy, or halo; or a pharmaceutically acceptable salt thereof.
- 11. The compound of claim 1 wherein R3 is (C1-C6)alkoxy, nitro, hydroxy, or halo; or R2 and R3 taken together are methylenedioxy.
- 12. The compound of claim 1 wherein R8 is (C1-C6)alkoxy, nitro, hydroxy or halo; or R7 and R8 taken together are methylenedioxy.
- 13. The compound of claim 1 wherein R7 is (C1-C6)alkoxy, nitro, hydroxy, or halo.
- 14. The compound of claim 1 wherein R6 is (C1-C6)alkoxy, nitro, hydroxy, or halo; or R6 and R7 taken together are methylenedioxy.
- 15. The compound of claim 1 which is a compound of formulae II:
- 16. The compound of claim 1 which is a compound of formulae III:
- 17. The compound of claim 1 which is a compound of formulae V:
- 18. The compound of claim 1 which is a compound of formulae VI:
- 19. The compound of claim 1 which is a compound of formulae VII:
- 20. The compound of claim 1 which is a compound of formulae VIII:
- 21. The compound of claim 1 which is a compound of formulae IX:
- 22. The compound of claim 1 which is a compound of formulae X:
- 23. The compound 2,3-Dimethoxy-dibenzo[c,h]cinnoline (6); 2,3-Dimethoxy-8,9-methylenedioxy-dibenzo[c,h]cinnoline (14); 2,3,8-Trimethoxydibenzo[c,h]cinnoline (60); 2,3,9-Trimethoxydibenzo[c,h]cinnoline (61); 9-Benzyloxy-2,3,8-trimethoxydibenzo[c,h]cinnoline (42); 2-Methoxy-8,9-methylenedioxydibenzo[c,h]cinnoline (43); or 3-Methoxy-8,9-methylenedioxydibenzo[c,h]cinnoline (44); or a pharmaceutically acceptable salt thereof.
- 24. The compound 2,3-Dimethoxy-8,9-methylenedioxy-dibenzo[c,h]cinnoline (14); or a pharmaceutically acceptable salt thereof.
- 25. The compound of claim 1 wherein R1-R3 and R6-R8 are not each hydrogen.
- 26. The compound of claim 1 wherein one of R2 and R8 is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro; or at least one of R2 and R8 forms part of a methylenedioxy;
- 27. The compound of claim 1 which is not 9-hydroxy-2,3,8-trimethoxydibenzo[c,h]cinnoline.
- 28. A pharmaceutical composition comprising a effective amount of a compound of formula I:
- 29. A pharmaceutical composition comprising a compound as described in claim 1 in combination with a pharmaceutically acceptable diluent or carrier.
- 30. A method of inhibiting cancer cell growth, comprising administering to a mammal afflicted with cancer, an amount of a compound as described in claim 1, effective to inhibit the growth of said cancer cells.
- 31. A method comprising inhibiting cancer cell growth by contacting said cancer cell in vitro or in vivo with an amount of a compound as described in claim 1, effective to inhibit the growth of said cancer cell.
- 32. A method of producing an antibacterial effect in a mammal in need of such treatment comprising administering to the mammal, an amount of a compound as described in claim 1, effective to provide an antibacterial effect.
- 33. A method of producing an antifungal effect in a mammal in need of such treatment comprising administering to the mammal, an amount of a compound as described in claim 1, effective to provide an antifungal effect.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation under 35 USC 111(a) of PCT/US00/29583 filed Oct. 26, 2000 (WO 01/32631 A3), which claimed priority from U.S. Provisional Patent Application Serial No. 60/162,540, filed Oct. 29, 1999, which applications are incorporated by reference.
GOVERNMENT FUNDING
[0002] The invention described herein was made with U.S. Government support under grant number CA39662 awarded by the National Cancer Institute. The United States Government has certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60162540 |
Oct 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US00/29583 |
Oct 2000 |
US |
Child |
10134983 |
Apr 2002 |
US |